Pediatric Heart Failure Pharmacotherapy: Transformative Insights for the Future

This review aims to summarize the status and future directions of pediatric heart failure (HF) pharmacotherapy. Notably, managing HF in children presents unique challenges due to heterogeneous etiologies and a longstanding paucity of pediatric-specific data. While historically reliant on adult-derived evidence, current treatment strategies are evolving through an integration of novel and pediatric-focused therapies. Indeed, present pediatric HF algorithms, adapted from adult guidelines, now include four pharmacologic pillars: angiotensin-converting enzyme (ACE) inhibitors/angiotensin receptor blockers/angiotensin receptor-neprilysin inhibitors (ARNIs), β-blockers, mineralocorticoid receptor antagonists, and sodium-glucose cotransporter-2 (SGLT2) inhibitors. Multicenter registries, such as the Pediatric HF Registry, the Pediatric Cardiomyopathy Registry (PCMR), and the Advanced Cardiac Therapies Improving Outcomes Network (ACTION) HF medication titration projects, are further shaping a more evidence-informed and personalized approach. A comprehensive literature search was conducted using PubMed, Scopus, and Google Scholar to identify recent review articles, clinical trials, and guideline documents relevant to pediatric HF pharmacotherapy. The search focused on articles published in the English language from the past decade, with particular attention to transformative therapeutic insights. Data from adult HF studies were also included to provide context and bridge gaps in pediatric evidence. Where available, pediatric-specific data were prioritized to inform applicability. Relevant findings were critically appraised, synthesized, and integrated to develop a cohesive narrative reflecting current trends and emerging directions in pharmacological management of pediatric HF. This review examined the evolving landscape of medical therapies for chronic pediatric HF, underscoring the limitations of a one-size-fits-all approach. The heterogeneity of underlying etiologies complicates the development of guideline-directed treatments tailored to children, particularly when attempting to stratify care by phenotypes such as heart failure with reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF), as is commonly practiced in adult populations. There is an urgent need to individualize treatment strategies based on the hemodynamic profile of each pediatric patient, advocating for the integration of precision-based care into guideline-directed medical therapy. Such an approach not only enhances clinical outcomes in a population marked by etiologic diversity and developmental variability but also informs scalable care models and future guideline frameworks that reflect the unique needs of children with HF.